Aboleris Pharma has closed a €27.3 million (US$28.7 million) series A financing, funds it plans to put toward progressing into the clinic a monoclonal antibody against a novel T-cell target with “first-in-class potential” to treat rheumatoid arthritis. The Gosselies, Belgium-based company’s antibody, ABO-21009, is designed to “rebalance” the immune system by inhibiting CD45RC, a protein expressed on the surface of a subset of disease-causing T cells.
The Global Health Innovative Technology (GHIT) Fund has announced new investments in the development of a new prophylactic vaccine against malaria, a new anti-malarial drug, and product development projects against neglected tropical diseases.
Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for its field. “Yes, I want to treat these patients, I want these patients to have a better life. But I also want drug discovery and development folks to think differently about discovering new drugs for the CNS,” Jay Lichter told BioWorld.
Everest Medicines Ltd. is in-licensing Kezar Life Sciences Inc.’s phase II autoimmune disease candidate, zetomipzomib in a deal worth $132 million for greater China, South Korea and southeast Asia rights. Kezar’s lead molecule zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Toleranzia AB has begun a regulatory GLP-toxicology study of TOL-2, being developed for myasthenia gravis. Animals will receive daily doses of TOL-2 on multiple days to determine the safety and tolerability of TOL-2.
Phylex Biosciences Inc. has announced plans to pursue the development of a nanoparticle mRNA vaccine against the Nipah virus. Last year, the company published proof of principle for its second-generation nanoparticle mRNA vaccine against the SARS-CoV-2 delta virus.
Everest Medicines Ltd. is in-licensing Kezar Life Sciences Inc.’s phase II autoimmune disease candidate, zetomipzomib in a deal worth $132 million for greater China, South Korea and southeast Asia rights. Kezar’s lead molecule zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Astellas Pharma Inc. and Mitobridge Inc. have synthesized stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of autoimmune diseases, neurodegeneration, type I interferonopathy and Sjögren’s syndrome.
RSS
